Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
March 05 2021 - 8:30AM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage
biopharmaceutical company, today announced that the Company’s
management will participate in two upcoming investor conferences in
March:
- The first conference will be the H.C. Wainwright Global Life
Sciences Conference, which is taking place March 9-10, 2021. The
Company will conduct one-on-one meetings with institutional
investors at this conference and a pre-recorded corporate overview
presentation by Richard A. Miller, M.D., president and chief
executive officer of Corvus, will be available to play on-demand
starting at 7:00 am ET on Tuesday, March 9.
- The second conference will be the 33rd Annual Roth Virtual
Conference, which is taking place March 15-17, 2021. Dr. Miller
will participate in a fireside chat at 2:30 pm ET / 11:30 am PT on
Tuesday, March 16 and the Company will conduct one-on-one meetings
with institutional investors at the conference. In addition, a
pre-recorded corporate overview presentation by Dr. Miller will be
made available beginning on Monday, March 8, 2021.
A webcast of the presentations and the fireside chat noted above
will be available via the investor relations section of the Corvus
website and replays will be available for 90 days following the
events. About Corvus
PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage
biopharmaceutical company. Corvus’ lead product candidate is
CPI-006, a humanized monoclonal antibody directed against CD73 that
has exhibited immunomodulatory activity and activation of immune
cells in preclinical studies. CPI-006 is being evaluated in a Phase
3 clinical trial for the treatment of hospitalized patients with
COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as
a single agent, in combination with ciforadenant and pembrolizumab.
The Company’s second clinical program, CPI-818, is an
investigational, oral, small molecule drug that selectively
inhibited ITK in preclinical studies, and is in a multicenter Phase
1/1b clinical trial in patients with several types of T-cell
lymphomas. Its third clinical program, ciforadenant (CPI-444), is
an oral, small molecule inhibitor of the A2A receptor.
INVESTOR CONTACT:Leiv LeaChief Financial
OfficerCorvus Pharmaceuticals,
Inc.+1-650-900-4522llea@corvuspharma.com
MEDIA CONTACT:Sheryl SeapyW2O
pure+1-949-903-4750sseapy@purecommunications.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2023 to Apr 2024